Perspektivy primeneniya ingibitora protonnoy pompy novogo pokoleniya - dekslansoprazola v terapii gastroezofageal'noy reflyuksnoy bolezni


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Current clinical guidelines recommend proton pump inhibitors (PPIs) as the treatment of choice and the most effective pharmacotherapy for treating acid-related disorders, specifically for gastroesophageal reflux disease (GERR). A novel PPI formulation dexlansoprazole is an R-enantiomer of lansoprazole. Currently marketed as Dexilant® modified release capsules, formulation capsules it has two distinct drug release periods with two peaks of T max (1-2 and 4-5 hours after meal) and, therefore, prolongs the plasma dexlansoprazole concentration. Evidence from several randomized clinical trials confirmed efficacy of dexlansoprazole in the treatment of different forms of GERD.

Full Text

Restricted Access

References

  1. El-Serag H., Hill C., Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol. Ther. 2008;29:470-80.
  2. Dent J., El-Serag H.B., Wallander M.A., Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710-7.
  3. Лазебник Л.Б., Машарова А.А., Бордин Д.С., Васильев Ю.В., Ткаченко Е.И., Абдулхаков Р.А., Бутов М.А., Еремина Е.Ю., Зинчук Л.И., Цуканов В.В. Многоцентровое исследование «Эпидемиология гастроэзофагеальной рефлюксной болезни в России» (МЭГРЕ): первые итоги. Эксперим. и клин. гастроэнтерология. 2009;6:4-12.
  4. Маев И.В., Андреев Д.Н., Дичева Д.Т. Гастроэзофагеальная рефлюксная болезнь: от патогенеза к терапевтическим аспектам. Consilium Medicum. 2013;8:30-4.
  5. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand. J. Gastroenterol. Suppl. 1993;199:18-21.
  6. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. М.: Шико, 2011.
  7. Маев И.В., Бурков С.Г., Юренев Г.Л. Гастроэзофагеальная рефлюксная болезнь и ассоциированная патология. М., 2014.
  8. Cook M.B., Corley D.A., Murray L.J., Liao L.M., Kamangar F., Ye W., Gammon M.D., Risch H.A., Casson A.G., Freedman N.D., Chow W.H., Wu A.H., Bernstein L., Nyrn O., Pandeya N., Whiteman D.C., Vaughan T.L. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One. 2014;9(7):e103508.
  9. Lassen A.T. Acid-related disorders and use of antisecretory medication. Dan. Med. Bull. 2007;54(1):18-30.
  10. Самсонов А., Андреев Д., Юренев Г., Лежнева Ю. Современные ингибиторы протонной помпы в терапии гастроэзофагеальной рефлюксной болезни. Врач. 2014;5:24-8.
  11. Richter J.E., Friedenberg F.K. Gastroesophageal reflux disease. In: Feldman M., Friedman L.S., Brandt L.J., eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier, 2010. Chap 43.
  12. Андреев Д.Н., Дичева Д.Т., Лебедева Е.Г., Парцваниа-Виноградова Е.В. Фармакологические основы применения ингибиторов протонной помпы. Фарматека. 2014; 12:64-9.
  13. Lanzon-Miller S., Pounder R.E., Hamilton M.R., Ball S., Chronos N.A., Raymond F., Olausson M., Cederberg C. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either Ranitidine or Omeprazole. Aliment. Pharmacol. Ther. 1987;1:239.
  14. Chiba N., Gara C.J., Wilkinson J.M., Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A metaanalysis. Gastroenterology. 1997;112:1798.
  15. van Pinxteren B., Numans M.E., Bonis P.A., Lau J. Short term treatment with proton pump inhibitors, H2RAs and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. 2004;3:CD002095.
  16. Cicala M., Emerenziani S., Guarino M.P., Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J. Gastroenterol. 2013;19(39): 6529-35.
  17. Moraes-Filho J.P. Refractory gastroesophageal reflux disease. Arq. Gastroenterol. 2012;49(4):296-301.
  18. Krznaric Z., Ljubas Kelecic D., Rustemovic N., Vranesic Bender D., Ostojic R., Markos P., Scarpignato C. Pharmaceutical principles of acid inhibitors: unmet needs. Dig. Dis. 2011;29(5):469-75.
  19. Johnson D.A., Katz P.O. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev. Gastroenterol. Disord. 2008;8(2):98-108.
  20. Tutuian R., Katz P.O., Castell D.O. Nocturnal acid breakthrough: pH, drugs and bugs. Eur. J. Gastroenterol. Hepatol. 2004;16(5):441-3.
  21. Scarpignato C., Pelosini I., Di Mario F. Acid suppression therapy: where do we go from here? Dig. Dis. 2005;24:7-42.
  22. Katz P.O., Scheiman J.M., Barkun A.N. Review article: acid-related disease - what are the unmet clinical needs? Aliment. Pharmacol. Ther. 2006;23(Suppl 2):S9-22.
  23. Chaudhry A.S., Kochhar R., Kohli K.K. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J. Med. Res. 2008;127(6):521-30.
  24. Saitoh T., Otsuka H., Kawasaki T., Endo H., Iga D., Tomimatsu M., Fukushima Y., Katsube T., Ogawa K., Otsuka K. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology. 2009;56(91-92):703-6.
  25. Chen J., Yuan Y.C., Leontiadis G.I., Howden C.W. Recent safety concerns with proton pump inhibitors. J. Clin. Gastroenterol. 2012;46(2):93-114
  26. Маев И.В., Самсонов А.А., Годило-Годлевский В.А., Андреев Д.Н., Дичева Д.Т. Лекарственное взаимодействие ингибиторов протонной помпы и клопидогрела при их совместном приеме. Клин. мед. 2013; 5:15-21.
  27. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut К., Le Calvez G., Mansourati J., Mottier D., Abgrall J.F., Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 2008;51:256-60.
  28. Dutta U., Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol. Clin. North. Am. 2013;42(1):93-117.
  29. Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения кислотозависимых заболеваний. Клинические перспективы гастроэнтерологии, гепатологии. 2014;2:15-24.
  30. Zhou Q., Yao T.W., Zeng S. Effects of stereochemical aspects on drug interaction in pharmacokinetics. Acta Pharmacol. Sin. 2002;23(5):385-92.
  31. Zhou Q., Yan X.F., Pan W.S., Zeng S. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? World J. Gastroenterol. 2008;14(16):2617-19.
  32. Miura M., Tada H., Yasui-Furukori N., Uno T., Sugawara K., Tateishi T., Suzuki T. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur. J. Clin. Pharmacol. 2004;60(9):623-28.
  33. Андреев Д.Н., Кучерявый Ю.А. Перспективы лечения гастроэзофагеальной рефлюксной болезни. Consilium Medicum. Гастроэнтерология. 2013;2:9-14.
  34. Mayer M.D., Vakily M., Witt G., Mulford D.J. The Pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and Lansoprazole 60 mg: a retrospective analysis. Gastroenterology. 2008;134(Suppl. 1):A-176.
  35. Metz D.C., Vakily M., Dixit T., Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment. Pharmacol. Ther. 2009;29(9):928-37.
  36. Vakily M., Zhang W., Wu J., Atkinson S., Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr. Med. Res. Opin. 2009;25:627-38.
  37. Kukulka M., Eisenberg C., Nudurupati S. Comparator pH study to evaluate the singledose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin. Exp. Gastroenterol. 2011;4:213-20.
  38. Boulanger L., Mody R., Bao Y., et al. Does the Dosing Frequency of Proton Pump Inhibitors (PPIs) Affect Medication Adherence Among Patients Diagnosed with Gastroesophageal Reflux Disease (GERD)? Gastroenterology. 2008;134(4 Suppl. 1):A321-2
  39. Lee R.D., Vakily M., Mulford D., Wu J.,Atkinson S.N. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment. Pharmacol. Ther. 2009;29(8):824-33.
  40. Behm B.W., Peura D.A. Dexlansoprazole MR for the management of gastroesophageal reflux disease. Expert Rev. Gastroenterol. Hepatol. 2011;5(4):439-45.
  41. Frelinger A.L. 3rd, Lee R.D., Mulford D.J., Wu J., Nudurupati S., Nigam A., Brooks J.K., Bhatt D.L., Michelson A.D. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J. Am. Coll. Cardiol. 2012;59(14):1304-11.
  42. Sharma P., Shaheen N.J., Perez M.C., Pilmer B.L., Lee M., Atkinson S.N., Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment. Pharmacol. Ther. 2009;29: 731-41.
  43. Peura D.A., Pilmer B., Hunt B., Mody R., Perez M.C. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment. Pharmacol. Ther. 2013;37(8):810-18.
  44. Fass R., Chey W.D., Zakko S.F., Andhivarothai N., Palmer R.N., Perez M.C., Atkinson S.N. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and night-time heartburn in patients with non-erosive reflux disease. Aliment. Pharmacol. Ther. 2009;29(12):1261-72.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies